What are the common side effects of lenvatinib/lenvatinib?

Lenvatinib (Lenvatinib) is a kinase inhibitor (targeted therapy) used to treat: As a first-line treatment for people with a type of liver cancer called hepatocellular carcinoma (HCC), which cannot be removed with surgery; A first-line treatment for adults with a type of thyroid cancer called differentiated thyroid cancer (DTC), for which radioactive iodine is no longer effective, and is gaining ground; in combination with everolimus to treat patients with advanced renal cell carcinoma (RCC) after a course of treatment with another anticancer therapy. It is available in capsule form, containing 4 mg or 10 mg of lenvatinib.

In clinical studies, the most common adverse events in patients receiving lenvatinib were hypertension, diarrhea, fatigue or asthenia, decreased appetite, weight loss, nausea, stomatitis, and palmoplantar erythrocytic dysplasia syndrome. Hypertension is one of the most common adverse reactions of lenvatinib treatment, which is more prominent in subjects over 75 years of age. In a phase III select trial of radioiodine-refractory DIC, fistula formation leading to tumor bleeding was reported in patients in the treatment arm. Adverse effects of treatment should be controlled by adjusting dosage and discontinuing treatment when necessary.

Warnings/Precautions in the U.S. manufacturer's preprescription information also include hypertension, cardiac dysfunction (decreased left or right ventricular function, heart failure, or pulmonary edema), arterial thrombosis Embolic events, hepatotoxicity, proteinuria, renal failure and damage, gastrointestinal perforation and fistula formation, QT interval prolongation, hypocalcemia, reversible posterior leukoencephalopathy syndrome, bleeding events, and impaired thyroid-stimulating hormone (TSH) suppression. Therefore, if patients need to use this drug for treatment, they should do so under the guidance of a doctor.